Etevritamab

艾替瑞妥单抗

Report date: 2026/03/19 17:23:44

Base Information

Drug NameEtevritamab
Drug Alias NameAnti-EGFRvIII/CD3 BiTE antibody (Amgen)AMG-596
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibodyBiologics > T cell engagers
Mechanisms of ActionEpidermal growth factor receptor variant III antagonistsT-cell surface glycoprotein CD3 epsilon chain modulators
TargetsEpidermal growth factor receptor variant IIIT-cell surface glycoprotein CD3 epsilon chain
Therapy Area/IndicationsGlioblastoma
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesNetherlandsAustralia +[6] 
CombinationsNo
Global Highest StatusDiscontinued (Phase 1 Clinical)
Highest Status in ChinaN/A
Originator CompaniesAmgen Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesBeOne Medicines LtdAmgen Inc
Active IndicationsN/A
Inactive IndicationsGlioblastoma

Other Information

ATC CodeN/A
Related LinksN/A